- Home
- RNAC vs TNGX Comparison
RNAC vs TNGX Comparison
Compare RNAC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- TNGX
- Stock Information
- Founded
- RNAC 2007
- TNGX 2014
- Country
- RNAC United States
- TNGX United States
- Employees
- RNAC N/A
- TNGX N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- TNGX Health Care
- Exchange
- RNAC Nasdaq
- TNGX Nasdaq
- Market Cap
- RNAC 428.2M
- TNGX 413.6M
- IPO Year
- RNAC 2016
- TNGX N/A
- Fundamental
- Price
- RNAC $19.29
- TNGX $2.85
- Analyst Decision
- RNAC Strong Buy
- TNGX Strong Buy
- Analyst Count
- RNAC 8
- TNGX 8
- Target Price
- RNAC $41.67
- TNGX $13.14
- AVG Volume (30 Days)
- RNAC 136.8K
- TNGX 1.2M
- Earning Date
- RNAC 03-06-2025
- TNGX 11-06-2024
- Dividend Yield
- RNAC N/A
- TNGX N/A
- EPS Growth
- RNAC N/A
- TNGX N/A
- EPS
- RNAC N/A
- TNGX N/A
- Revenue
- RNAC $47,938,000.00
- TNGX $43,383,000.00
- Revenue This Year
- RNAC $56.02
- TNGX $27.73
- Revenue Next Year
- RNAC N/A
- TNGX N/A
- P/E Ratio
- RNAC N/A
- TNGX N/A
- Revenue Growth
- RNAC N/A
- TNGX 15.67
- 52 Week Low
- RNAC $11.67
- TNGX $2.59
- 52 Week High
- RNAC $41.87
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- RNAC 53.24
- TNGX 41.79
- Support Level
- RNAC $18.27
- TNGX $2.60
- Resistance Level
- RNAC $20.12
- TNGX $3.65
- Average True Range (ATR)
- RNAC 1.25
- TNGX 0.25
- MACD
- RNAC 0.20
- TNGX 0.01
- Stochastic Oscillator
- RNAC 77.69
- TNGX 24.88
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.